Pharmacological Intervention to Modulate HDL: What Do We Target? by Nicholas J. Woudberg, Sarah Pedretti, Sarah Pedretti, Sandrine Lecour, Rainer Schulz, Nicolas Vuilleumier, Richard W. James, Miguel A. Frias, Miguel A. Frias

Get full text

HDL protects against myocardial ischemia reperfusion injury via miR-34b and miR-337 expression which requires STAT3. by Sarah Pedretti, Marie-Claude Brulhart-Meynet, Fabrizio Montecucco, Sandrine Lecour, Richard W James, Miguel A Frias

Get full text

Ferritin: A Biomarker Requiring Caution in Clinical Decision by Baptiste Lemaire, Miguel A. Frias, Olivier Golaz, Jean-Luc Magnin, Véronique Viette, Nicolas Vuilleumier, Sophie Waldvogel Abramowski

Get full text

People living with HIV display increased anti-apolipoprotein A1 auto-antibodies, inflammation, and kynurenine metabolites: a case–control study by Miguel A. Frias, Miguel A. Frias, Sabrina Pagano, Sabrina Pagano, Nasim Bararpour, Nasim Bararpour, Nasim Bararpour, Jonathan Sidibé, Festus Kamau, Vanessa Fétaud-Lapierre, Vanessa Fétaud-Lapierre, Peter Hudson, Aurélien Thomas, Aurélien Thomas, Sandrine Lecour, Hans Strijdom, Nicolas Vuilleumier, Nicolas Vuilleumier

Get full text

Sphingosine‐1‐phosphate as a key player of insulin secretion induced by high‐density lipoprotein treatment by Marie‐Claude Brulhart‐Meynet, Aurélien Thomas, Jonathan Sidibé, Florian Visentin, Rodolphe Dusaulcy, Valérie Schwitzgebel, Zoltan Pataky, Jacques Philippe, Nicolas Vuilleumier, Richard W. James, Yvan Gosmain, Miguel A. Frias

Get full text